RESUMEN
Evaluation of the various pharmacognostic quality parameters and DNA fingerprint of Saudi Arabian medicinal plant namely Datura stramonium growing in Asir region was the objective of the study. The pharmacognostical parameters were done in terms of macroscopic characters, microscopic details, physico-chemical evaluations, phytochemical analysis, fluorescence analysis and DNA fingerprint by using standard techniques and random polymorphic DNA primer. The detailed microscopy of the leaf revealed the presence of pre-medullary phloem, xylem, endodermis, parenchymatous pericycle, lower epidermis and calcium oxalate crystals. There are various amounts of foreign material, ash values, moisture content and extractive values, found after estimations. Preliminary phytochemical screening exhibited the presence of alkaloids, flavonoids, glycosides, tannins and sterols in variable amounts. Random amplified polymorphic DNA (RAPD) showed there are a prominent scorbale DNA bands. These evaluations provided referential information for correct authentication and quality standardization of the important medicinal plant material. These information will also be supportive to differentiate Datura stramonium from the closely related other species.
Asunto(s)
Dermatoglifia del ADN , ADN de Plantas/genética , Datura stramonium/química , Datura stramonium/genética , Farmacognosia , Fitoquímicos/análisis , Hojas de la Planta/química , Hojas de la Planta/genética , Datura stramonium/crecimiento & desarrollo , Hojas de la Planta/crecimiento & desarrollo , Control de Calidad , Arabia SauditaRESUMEN
Cardiovascular disorders constitute the principal cause of deaths worldwide and will continue as the major disease-burden by the year 2060. A significant proportion of heart failures occur because of use and misuse of drugs and most of the investigational agents fail to achieve any clinical relevance. Here, we investigated rosuvastatin and retinoic acid for their "pharmacological pleiotropy" against high dose ß-adrenergic agonist (isoproterenol)-induced acute myocardial insult. Rats were pretreated with rosuvastatin and/or retinoic acid for seven days and the myocardial injury was induced by administering isoproterenol on the seventh and eighth day. After induction, rats were anaesthetized for electrocardiography, then sacrificed and different samples were collected/stored for various downstream assays. Myocardial injury with isoproterenol resulted in increased cardiac mass, decreased R-wave amplitude, increased QRS and QT durations; elevated levels of cardiac markers like cTnI, CK-MB, ALT and AST; increased lipid peroxidation, protein carbonylation and tissue nitric oxide levels; decreased endogenous antioxidants like SOD, CAT, GR, GST, GPx and total antioxidant activity; increased inflammatory markers like TNF-α and IL-6; decreased the mRNA expression of Nrf2 and Bcl-2; increased the mRNA expression of Bax, eNOS and iNOS genes. Pretreatment with rosuvastatin and/or retinoic acid mitigated many of the above biochemical and pathological alterations. Our results demonstrate that rosuvastatin and retinoic acid exert cardioprotective effects and may act as potential agents in the prevention of ß-adrenergic agonist-induced acute myocardial injury in rats. Cardioprotective potential of rosuvastatin and retinoic acid could be attributed to their influence on the redox pathways, immunomodulation, membrane stability, Nrf2 preservation, iNOS and Bax expression levels. Thus, they may act directly or indirectly at various steps, the breakpoints, in the pathophysiological cascade responsible for cardiac injury. Our study gives insights about the pharmacological pleiotropism of rosuvastatin and retinoic acid.
Asunto(s)
Isoproterenol/toxicidad , Infarto del Miocardio/inducido químicamente , Infarto del Miocardio/prevención & control , Rosuvastatina Cálcica/farmacología , Transducción de Señal/efectos de los fármacos , Tretinoina/farmacología , Agonistas Adrenérgicos beta/toxicidad , Animales , Anticolesterolemiantes/farmacología , Antineoplásicos/uso terapéutico , Peso Corporal/efectos de los fármacos , Corazón/anatomía & histología , Corazón/efectos de los fármacos , Masculino , Tamaño de los Órganos , Distribución Aleatoria , Ratas , Ratas WistarRESUMEN
BACKGROUND/AIMS: Irritable bowel syndrome (IBS) is a chronic psycho-physiological disorder. It is considered to be the most common functional gastrointestinal disorder, and about 50–90% of IBS patients have associated psychiatric co-morbidity. We aimed to study psychiatric co-morbidities in patients with IBS visiting a tertiary care center. METHODS: This was a cross-sectional case-control study conducted over a duration of one and a half years from January 2014 to July 2015. Patients were selected from the out-patient department of gastroenterology. About 160 patients with IBS who fulfilled the inclusion criteria and who gave written informed consent were selected as study cases. The healthy attendants of cases were selected as controls. A total of 200 controls were selected. Rome-III criteria were used to diagnose IBS. For diagnosing psychiatric disorders, we used the Mini International Neuropsychiatric Interview Schedule Plus. RESULTS: Mean age of our cases and controls was 39.7 ± 11.4 and 37.7 ± 9.6 years, respectively. Females outnumbered males in our cases as well as their controls by a ratio of 2:1 approximately. Psychiatric disorders were seen in 84.4% of IBS patients as compared to 41.5% in controls. Major psychiatric disorders seen in our patients were generalized anxiety disorders (30.0%) and depression (28.0%). CONCLUSIONS: The majority of patients with IBS who present to a tertiary care center have co-morbid psychiatric disorders. We need to screen these patients for such co-morbidities and develop a holistic approach for better outcome in such cases.